Sponsors (31)
Introduced March 5, 2026 by Mark Takano · Last progress March 5, 2026
The bill greatly expands and enforces access to no‑cost HIV prevention and outreach—especially for low‑income, uninsured, and other high‑risk groups—while shifting substantial program, administrative, and litigation costs onto insurers, governments, and potentially taxpayers, with privacy and implementation trade‑offs.
Millions of people with private insurance, Medicaid/CHIP, Medicare, veterans/TRICARE/VA, and other federal programs will get FDA‑approved HIV prevention drugs, related labs, and follow‑up with no cost‑sharing and fewer prior‑authorization barriers, reducing out‑of‑pocket costs and improving timely access to prevention.
Uninsured and underinsured people and communities disproportionately affected by HIV will gain funded access to PrEP/PEP, outreach, adherence support, and provider education, increasing prevention uptake and reducing transmission in high‑need populations.
People covered as dependents on family health plans can obtain recommended preventive services (including sensitive services) confidentially without notice to other enrollees, protecting privacy and encouraging uptake of services like STI screening and contraception.
Taxpayers and state budgets will face increased costs as federal, state, and program spending expands to pay for no‑cost HIV prevention coverage and grant‑funded outreach, and some markets may face higher insurance premiums over time.
Insurers, self‑funded plans, states, and plan administrators will incur substantial administrative and compliance costs to change systems, report data annually, and adapt Medicaid/CHIP, which could be passed on to consumers or require state legislative/action.
Narrow exceptions and new benefit rules could encourage formulary steering or other benefit design changes that limit access to specific drugs or create disputes over permissible underwriting, potentially restricting patient choice.
Based on analysis of 20 sections of legislative text.
Mandates no‑cost coverage of FDA‑approved PrEP/PEP and related services, restricts prior authorization, funds education and grants to expand access, and creates enforcement plus a private right of action.
Requires private group and individual health plans to cover FDA‑approved HIV prevention drugs (PrEP and PEP) and related services without cost‑sharing and largely without prior authorization, expands education and grant programs to increase access (especially for uninsured and underinsured people), protects confidentiality for family plan users, bans discrimination by life/disability/long‑term care insurers for PrEP/PEP use, and creates federal monitoring, reporting, enforcement mechanisms plus a private right of action for violations.